Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK ( TheStreet) -- It's hard to believe that just nine years ago Google ( GOOG) had its initial public offering, Jim Cramer said on "Mad Money" Monday. But in that nine years, Google's stock has rallied 900%, making shareholders a ton of money. What's more unbelievable, however, is there are nine other stocks that have far outperformed Google over the past nine years, said Cramer. All of them have been accessible to every investor. Topping his list of the nine best-performing stocks in the past nine years is Priceline.com ( PCLN), everyone's favorite travel Web site. That stock has risen 4,598%, a remarkable run. Priceline is followed by Monster Beverage ( MNST) and Apple ( AAPL), a stock Cramer owns for his charitable trust,
Healthy Food, Healthy StocksThe natural and organic food sector has been on fire, Cramer told viewers, but even in a $63 billion industry that's expected to grow 9.5% this year it pays to stick with the best-of-breed stocks. That's why for the first installment of his "Cramer's Cookout" series, Cramer recommended Whole Foods Market ( WFM) as his best-in-show pick. Cramer said Whole Foods has something most companies only dream of -- customer trust and loyalty. That's why the company's 340 locations are booming. Whole Foods expects to open 33 to 38 new locations, representing 8% to 9% growth overall -- not bad for a group that struggles to deliver 2% to 3% growth. Yet, Whole Foods shares still only trade for 30 times earnings despite its 19% growth rate.
Then there's Fresh Market ( TFM), which has 130 locations. Cramer said this stock trades at 28 times earnings with a 20% growth rate, but he worries about the company's regional to national plans as it attempts to enter Whole Foods' and Trader Joe's home turf of the Northeast. Natural Grocers ( NGVC), is a newcomer to the organic grocer scene, debuting last year and seeing 119% growth since its IPO. Cramer said this stock is simply too expensive trading at 58 times earnings. He was equally unimpressed with Sprouts Farmers Market ( SFM), another fresh IPO that's rallied 122% since its debut.
Cramer's Cookout, Part 2Next up on "Cramer's Cookout" were the organic food stocks of Hain Celestial ( HAIN), Annie's ( BNNY) and WhiteWave Foods ( WWAV). Cramer said all three companies produce great natural and organic food products, but that doesn't mean their stocks are just as tasty. Cramer said that while WhiteWave focuses on soy and almond milk along with lines of dairy and non-dairy creamers, Hain and Annie's are more broad-line plays, with many products in multiple categories and more being added all the time. That means while WhiteWave is not seeing a lot of commodity pressures, Hain and Annie's are more susceptible to such pressures. Annie's reported an earnings miss of 2 cents a share but was able to reaffirm its year-to-date guidance. WhiteWave recently reported in-line earnings, as did Hain. But when it comes to these companies' stocks, Cramer noted that Annie's sells for 36 times earnings with a 22% growth rate, giving it a PEG ratio of 1.7, which is pricey by Cramer's standards. He said that both Hain, which has a PEG or 1.5, and WhiteWave, at 1.3, are far more favorable. With earnings rapidly approaching, Cramer said he'd only put on a small position now and wait for the release before buying more.
Lightning RoundIn the Lightning Round, Cramer was bullish on American Electric Power ( AEP), Costco ( COST) and Nokia ( NOK). Cramer was bearish on Spartan Stores ( SPTN), Sysco ( SYY), AES Corp ( AES), Select Comfort ( SCSS) and Himax Technologies ( HIMX).
Executive Decision: Tom PikeIn the "Executive Decision" segment, Cramer sat down with Tom Pike, CEO of Quintiles Transnational ( Q), the newly minted clinical trial outsourcing company that just beat earnings expectations by 4 cents a share on its first quarter as a publicly traded company. Pike said Quintiles performs best when it receives full-service contracts from its customers, which allows the company to both design and execute clinical trials as well as provide observations and studies after the trial has been completed. He said the full-service approach offers customers a faster, more efficient approval path for the drugs their working on. Quintiles has a very experienced team that works directly with the U.S. Food and Drug Administration, Pike explained, which makes its services extremely valuable.
Quintiles also provides other services for drug makers, including offering a team of sales reps and sales educators that can help get the word out to doctors and practitioners after a drug has been approved. Pike said 27% of Quintiles' business currently stems from biotech firms, with the rest coming from larger, more established drug makers. When asked about cancellations, Pike said those are part of the unpredictable drug business, unfortunately. However, Quintiles is not seeing cancellations ahead of what was expected. Cramer said it should be easy to see why he's a fan of Quintiles, even if the company is, as yet, largely unknown on Wall Street.